CNSC Practice
Questions and
Answers Updated
2026
InBanBintensiveBcareBsetting,BwhichBofBtheBfollowingBcomplicationsBassociatedBwithBm
alnutritionBisBmostBlikelyBtoBoccurBasBaBresultBofBtheBfailureBtoBbeginBnutritionBsupp
ortBearlyBinBtheBtreatmentBregimen?B-BAnswerIncreasedBserumBlevelsBofBprotein-
boundBdrugs
WhichBofBtheBfollowingBisBtheBinpatientBglycemicBtargetBforBcriticallyBillBpatients?B
1:B80-110Bmg/dL
B2:B140-180Bmg/dL
B3:B181-210Bmg/dL
B4:B211-240Bmg/dLB-BAnswer2:B140-180Bmg/dL
TargetsB<110mg/dLBareBnotBrecommended
UnderBconditionsBofBsepsisBandBstress,BwhichBofBtheBfollowingBmetabolicBalterationsB
areBmostBlikelyBtoBoccur?B
1:BIncreasedBglucoseBproductionBandBincreasedBglucoseBuptake
2:BIncreasedBglucoseBproductionBandBdecreasedBglucoseBuptake
3:BDecreasedBglucoseBproductionBandBdecreasedBglucoseBuptake
,4:BDecreasedBglucoseBproductionBandBincreasedBglucoseBuptakeB-
BAnswer2:BIncreasedBglucoseBproductionBandBdecreasedBglucoseBuptake
StressBhormonesBinduceBinsulinBresistanceBandBhyperglycemiaBisBcommonlyBobservedB
withBnutritionBsupport.BItBisBrecommendedBthatBglucoseBlevelsBbeBadequatelyBcontroll
edBtoBavoidBpolyuriaBandBelectrolyteBdisturbances.
WhichBofBtheBfollowingBimmunomodulatingBnutrientsBmayBbeBharmfulBinBpatientsBwit
hBsevereBsepsis?B
1:BArginine
2:BSelenium
3:BNucleicBacids
4:BOmega-3BfattyBacidsB-BAnswer1:BArginine
NitricBoxideBcanBbeBdetrimentalBbyBleadingBtoBcoagulationBabnormalitiesBandBaltered
BhemodynamicBstatus.BInBthisBcase,BarginineBcouldBbeBconsideredBharmful.BBecauseBo
fBtheseBeffects,BthereBisBstillBmuchBdebateBoverBtheBvalueBofBarginineBinBnutritionBs
upportBforBcriticallyBillBpatients.
WhichBofBtheBfollowingBbestBdescribesBenteralBglutamineBsupplementationBinBtheBcriti
callyBillBpatientBnotBinBmultiBorganBfailure?B
1:BEnteralBglutamineBdecreasesBmortality
2:BEnteralBglutamineBdecreasesBventilatorBdays
3:BEnteralBglutamineBdecreasesBhospitalBlengthBofBstay
4:BEnteralBglutamineBdecreasesBnosocomialBinfectionsB-
BAnswer4:BEnteralBglutamineBdecreasesBnosocomialBinfections
,WhichBofBtheBfollowingBareBcounter-
regulatoryBhormonesBresponsibleBforBtheBhypercatabolismBobservedBinBcriticallyBillBtra
umaBpatients?B
1:BGlycogen,Binsulin,Bnorepinephrine
B2:BGlucagon,Bepinephrine,Bcortisol
B3:BGlycerol,Bserotonin,Bthymoglobulin
B4:BGlycerin,Bleptin,BadenosineB-BAnswer2:BGlucagon,Bepinephrine,Bcortisol
InBpatientsBwithBburns,BprovidingBcaloricBsupportBaboveBenergyBexpenditureBhasBbee
nBfoundBtoB
1:BsignificantlyBdecreaseBhospitalBlengthBofBstay.
2:BimproveBwoundBhealingBandBgraftBsuccess.
3:BdecreaseBfatBaccumulationBandBsteatosis.
4:BhaveBnoBeffectBonBpreservationBofBleanBbodyBmass.B-
BAnswer4:BhaveBnoBeffectBonBpreservationBofBleanBbodyBmass.
AlthoughBpatientsBwithBburnsBhaveBincreasedBneeds,BfeedingBinBexcessBofBenergyBexp
enditureBmayBcauseBhyperglycemia,BhepaticBsteatosis,BandBprolongedBventilatorBdepen
dence.BOneBstudyBofBcriticallyBillBburnBpatientsBshowedBthatBcaloricBdeliveryBbeyondB
1.2BxBmeasuredBrestingBenergyBexpenditureBdidBnotBconserveBleanBbodyBmassBbutBw
asBassociatedBwithBincreasedBfatBmassBaccumulation.
InBpulmonaryBinsufficiency,BexcessiveBcalorieBadministrationBmayBcauseBincreasedBbloo
dBpCO2BresultingBinB
1:BmetabolicBacidosis.
B2:BmetabolicBalkalosis.
B3:BrespiratoryBacidosis.
B4:BrespiratoryBalkalosis.B-BAnswer3:BrespiratoryBacidosis.
, WhichBofBtheBfollowingBisBtrueBofBessentialBfattyBacidBdeficiencyB(EFAD)BinBpatientsB
withBcysticBfibrosisB(CF)?B
1:BRoutineBsupplementationBofBomega-
3BfattyBacidsBisBessentialBinBtheBmanagementBofBCF
2:BEFADBusuallyBdoesBnotBmanifestBinBCFBpatientsBuntilBtheBsecondBdecade.
3:BCFBpatientsBwithoutBpancreaticBinsufficiencyBrarelyBdevelopBEFAD
4:BEFABprofilesBhaveBbeenBshownBtoBimproveBinBCFBpatientsBafterBlungBtransplantatio
nB-
BAnswer4:BEFABprofilesBhaveBbeenBshownBtoBimproveBinBCFBpatientsBafterBlungBtrans
plantation
EFABstatusBisBusuallyBevaluatedBbyBmeasuringBtheBtriene:BtetraeneBratio.BAlthoughBsu
pplementationBwithBomegaB3BfattyBacidsBareBsometimesBusedBinBtheBmanagementBof
BCF,BresultsBfromBclinicalBtrialsBhaveBshownBmixedBresultsBandBfurtherBtrialsBareBnee
dedBtoBdetermineBtheBefficacyBofBroutineBEFABsupplementationBinBtheBmanagementB
ofBCF.
WhichBofBtheBfollowingBisBtheBbestBchoiceBforBfeedingBaBpancreaticBinsufficientBinfan
tBwithBcysticBfibrosis?B
1:BProteinBhydrolysateBformulaBwithBmediumBchainBtriglycerideB(MCT)
B2:BFreeBaminoBacidBformulaBwithBMCT
B3:BHumanBmilk
B4:BStandardBinfantBformulaB-
BAnswerHumanBmilkBisBtheBoptimalBchoiceBoverBstandardBformulaBforBanyBinfantBdue
BtoBmultipleBbeneficialBcomponentsBincludingBimmunologicBproperties,BgrowthBfactors,
BandBbothBpre-
BandBprobiotics.BHumanBmilkBorBstandardBinfantBformulaBwithBappropriateBenzymeBd
osingBisBrecommended.BProteinBhydrolysateBorBfreeBaminoBacidBformulasBcontainingB
MCTBareBnotBindicatedBforBinfantsBwithBcysticBfibrosisB(CF)BunlessBthereBisBanotherB
Questions and
Answers Updated
2026
InBanBintensiveBcareBsetting,BwhichBofBtheBfollowingBcomplicationsBassociatedBwithBm
alnutritionBisBmostBlikelyBtoBoccurBasBaBresultBofBtheBfailureBtoBbeginBnutritionBsupp
ortBearlyBinBtheBtreatmentBregimen?B-BAnswerIncreasedBserumBlevelsBofBprotein-
boundBdrugs
WhichBofBtheBfollowingBisBtheBinpatientBglycemicBtargetBforBcriticallyBillBpatients?B
1:B80-110Bmg/dL
B2:B140-180Bmg/dL
B3:B181-210Bmg/dL
B4:B211-240Bmg/dLB-BAnswer2:B140-180Bmg/dL
TargetsB<110mg/dLBareBnotBrecommended
UnderBconditionsBofBsepsisBandBstress,BwhichBofBtheBfollowingBmetabolicBalterationsB
areBmostBlikelyBtoBoccur?B
1:BIncreasedBglucoseBproductionBandBincreasedBglucoseBuptake
2:BIncreasedBglucoseBproductionBandBdecreasedBglucoseBuptake
3:BDecreasedBglucoseBproductionBandBdecreasedBglucoseBuptake
,4:BDecreasedBglucoseBproductionBandBincreasedBglucoseBuptakeB-
BAnswer2:BIncreasedBglucoseBproductionBandBdecreasedBglucoseBuptake
StressBhormonesBinduceBinsulinBresistanceBandBhyperglycemiaBisBcommonlyBobservedB
withBnutritionBsupport.BItBisBrecommendedBthatBglucoseBlevelsBbeBadequatelyBcontroll
edBtoBavoidBpolyuriaBandBelectrolyteBdisturbances.
WhichBofBtheBfollowingBimmunomodulatingBnutrientsBmayBbeBharmfulBinBpatientsBwit
hBsevereBsepsis?B
1:BArginine
2:BSelenium
3:BNucleicBacids
4:BOmega-3BfattyBacidsB-BAnswer1:BArginine
NitricBoxideBcanBbeBdetrimentalBbyBleadingBtoBcoagulationBabnormalitiesBandBaltered
BhemodynamicBstatus.BInBthisBcase,BarginineBcouldBbeBconsideredBharmful.BBecauseBo
fBtheseBeffects,BthereBisBstillBmuchBdebateBoverBtheBvalueBofBarginineBinBnutritionBs
upportBforBcriticallyBillBpatients.
WhichBofBtheBfollowingBbestBdescribesBenteralBglutamineBsupplementationBinBtheBcriti
callyBillBpatientBnotBinBmultiBorganBfailure?B
1:BEnteralBglutamineBdecreasesBmortality
2:BEnteralBglutamineBdecreasesBventilatorBdays
3:BEnteralBglutamineBdecreasesBhospitalBlengthBofBstay
4:BEnteralBglutamineBdecreasesBnosocomialBinfectionsB-
BAnswer4:BEnteralBglutamineBdecreasesBnosocomialBinfections
,WhichBofBtheBfollowingBareBcounter-
regulatoryBhormonesBresponsibleBforBtheBhypercatabolismBobservedBinBcriticallyBillBtra
umaBpatients?B
1:BGlycogen,Binsulin,Bnorepinephrine
B2:BGlucagon,Bepinephrine,Bcortisol
B3:BGlycerol,Bserotonin,Bthymoglobulin
B4:BGlycerin,Bleptin,BadenosineB-BAnswer2:BGlucagon,Bepinephrine,Bcortisol
InBpatientsBwithBburns,BprovidingBcaloricBsupportBaboveBenergyBexpenditureBhasBbee
nBfoundBtoB
1:BsignificantlyBdecreaseBhospitalBlengthBofBstay.
2:BimproveBwoundBhealingBandBgraftBsuccess.
3:BdecreaseBfatBaccumulationBandBsteatosis.
4:BhaveBnoBeffectBonBpreservationBofBleanBbodyBmass.B-
BAnswer4:BhaveBnoBeffectBonBpreservationBofBleanBbodyBmass.
AlthoughBpatientsBwithBburnsBhaveBincreasedBneeds,BfeedingBinBexcessBofBenergyBexp
enditureBmayBcauseBhyperglycemia,BhepaticBsteatosis,BandBprolongedBventilatorBdepen
dence.BOneBstudyBofBcriticallyBillBburnBpatientsBshowedBthatBcaloricBdeliveryBbeyondB
1.2BxBmeasuredBrestingBenergyBexpenditureBdidBnotBconserveBleanBbodyBmassBbutBw
asBassociatedBwithBincreasedBfatBmassBaccumulation.
InBpulmonaryBinsufficiency,BexcessiveBcalorieBadministrationBmayBcauseBincreasedBbloo
dBpCO2BresultingBinB
1:BmetabolicBacidosis.
B2:BmetabolicBalkalosis.
B3:BrespiratoryBacidosis.
B4:BrespiratoryBalkalosis.B-BAnswer3:BrespiratoryBacidosis.
, WhichBofBtheBfollowingBisBtrueBofBessentialBfattyBacidBdeficiencyB(EFAD)BinBpatientsB
withBcysticBfibrosisB(CF)?B
1:BRoutineBsupplementationBofBomega-
3BfattyBacidsBisBessentialBinBtheBmanagementBofBCF
2:BEFADBusuallyBdoesBnotBmanifestBinBCFBpatientsBuntilBtheBsecondBdecade.
3:BCFBpatientsBwithoutBpancreaticBinsufficiencyBrarelyBdevelopBEFAD
4:BEFABprofilesBhaveBbeenBshownBtoBimproveBinBCFBpatientsBafterBlungBtransplantatio
nB-
BAnswer4:BEFABprofilesBhaveBbeenBshownBtoBimproveBinBCFBpatientsBafterBlungBtrans
plantation
EFABstatusBisBusuallyBevaluatedBbyBmeasuringBtheBtriene:BtetraeneBratio.BAlthoughBsu
pplementationBwithBomegaB3BfattyBacidsBareBsometimesBusedBinBtheBmanagementBof
BCF,BresultsBfromBclinicalBtrialsBhaveBshownBmixedBresultsBandBfurtherBtrialsBareBnee
dedBtoBdetermineBtheBefficacyBofBroutineBEFABsupplementationBinBtheBmanagementB
ofBCF.
WhichBofBtheBfollowingBisBtheBbestBchoiceBforBfeedingBaBpancreaticBinsufficientBinfan
tBwithBcysticBfibrosis?B
1:BProteinBhydrolysateBformulaBwithBmediumBchainBtriglycerideB(MCT)
B2:BFreeBaminoBacidBformulaBwithBMCT
B3:BHumanBmilk
B4:BStandardBinfantBformulaB-
BAnswerHumanBmilkBisBtheBoptimalBchoiceBoverBstandardBformulaBforBanyBinfantBdue
BtoBmultipleBbeneficialBcomponentsBincludingBimmunologicBproperties,BgrowthBfactors,
BandBbothBpre-
BandBprobiotics.BHumanBmilkBorBstandardBinfantBformulaBwithBappropriateBenzymeBd
osingBisBrecommended.BProteinBhydrolysateBorBfreeBaminoBacidBformulasBcontainingB
MCTBareBnotBindicatedBforBinfantsBwithBcysticBfibrosisB(CF)BunlessBthereBisBanotherB
